Chronic Kidney Disease

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."

A higher ratio of red blood cell distribution width to albumin was tied to greater all-cause, cardiovascular, and cancer mortality in adults with CKD.

A real-world study found that adding a GLP-1 to SGLT2 inhibitor therapy was associated with lower kidney, cardiovascular, and mortality risks in CKD.

The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

A higher weight-adjusted waist index (WWI) was independently linked to greater all-cause and CVD mortality in CKD, partly via inflammation.

Low fruit and vegetable intake alongside high sodium consumption remain top dietary drivers of CKD burden, with disparities by region, age, and income.

ORIGIN trial data suggest atacicept (Trutakna; Vera Therapeutics) is well tolerated in IgA nephropathy, with follow-up needed to assess long-term kidney outcomes.

The FDA approval of atacicept introduces the first BAFF/APRIL dual inhibitor for IgA nephropathy, with trial data showing significant proteinuria reduction.

Paricalcitol shows more consistent parathyroid hormone control and a stronger survival signal than calcitriol in chronic kidney disease, though evidence for hard outcomes remains limited.

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.

Global early-onset CKD mortality declined from 1990 to 2021, but incidence rose, highlighting persistent disparities and prevention needs.

Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial.

OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

Worse kidney function and higher proteinuria at biopsy predicted significantly greater health care use over 2 years in patients with IgA nephropathy.

This publication was developed with the support of Boehringer Ingelheim Pharmaceuticals, Inc.

Systematic review finds SGLT2 inhibitors and newer CKD drugs boost QALYs and often save costs by delaying dialysis and transplant.

Kirk Campbell, MD, discusses why FSGS is traditionally difficult to treat, the significance of the sparsentan approval, and future access needs.

The benefits of exercise are particularly notable for patients who are dependent upon dialysis, a new review suggests.

At 24 months, patients receiving iptacopan had approximately half the decline in estimated glomerular filtration rate slope compared to those receiving placebo.

Focal segmental glomerulosclerosis can lead to protein leakage in urine and hypertension; the condition is not considered curable at present, only manageable.